走進婦聯

array(29) { ["thumbs"]=> array(1) { [0]=> array(2) { ["id"]=> int(362205) ["url"]=> string(52) "/a/10001/201906/0db0122a23e8e984eec65429da2b5135.jpg" } } ["tags"]=> array(5) { [0]=> string(6) "患者" [1]=> string(6) "治療" [2]=> string(6) "復發" [3]=> string(9) "乳腺癌" [4]=> string(9) "內分泌" } ["sort"]=> int(0) ["terms"]=> array(8) { [0]=> int(249) [1]=> int(24618) [2]=> int(56209) [3]=> int(21346) [4]=> int(27467) [5]=> int(44878) [6]=> int(77067) [7]=> int(21011) } ["appid"]=> int(1) ["recommend"]=> int(0) ["catids"]=> string(6) ",75,7," ["url"]=> string(41) "http://www.mkxyk.com/zjfl/p/3003194.html" ["title"]=> string(39) "45-59歲女性為乳腺癌高發人群 " ["description"]=> string(207) "因此，術后系統規范的多學科綜合治療是降低復發轉移的重要措施，對于激素受體陽性復發高危的患者，延長內分泌治療可進一步降低乳腺癌患者的復發風險" ["sourceurl"]=> string(0) "" ["published"]=> int(1562029745) ["thumb"]=> array(2) { ["id"]=> int(362205) ["url"]=> string(52) "/a/10001/201906/0db0122a23e8e984eec65429da2b5135.jpg" } ["comments"]=> int(0) ["thumb_ratio"]=> int(1) ["id"]=> string(7) "3003194" ["tran_published"]=> string(10) "2019-07-02" ["model"]=> string(0) "" ["is_hot_content"]=> bool(false) ["pv"]=> int(0) ["virtual_pv"]=> int(161) ["click_pv"]=> int(0) ["virtual_digg"]=> int(1) ["shares"]=> int(0) ["digg"]=> int(1) ["all_pv"]=> int(0) ["author"]=> array(2) { [0]=> string(6) "葉禎" [1]=> string(9) "張雪奇" } ["content_terms"]=> array(3) { [1]=> array(2) { [0]=> string(6) "葉禎" [1]=> string(9) "張雪奇" } [4]=> array(1) { [0]=> string(22) "南寧云-南寧晚報" } [2]=> array(5) { [0]=> string(9) "乳腺癌" [1]=> string(6) "治療" [2]=> string(6) "復發" [3]=> string(9) "內分泌" [4]=> string(6) "患者" } } ["source"]=> string(22) "南寧云-南寧晚報" }